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Abstract
Background: This study examined the effects of a mixture of highly bioavailable omega-3 carboxylic acids (OM3-CA)
on nuclear magnetic resonance spectroscopy–assessed lipoprotein particle concentrations and sizes and other
cardiovascular risk markers in statin-treated patients with fasting triglycerides (TG) ≥2.3 mmol/L (200 mg/dL)
and <5.6 mmol/L (500 mg/dL) and at high cardiovascular risk.
Methods: After a diet lead-in and statin-stabilization period, 647 patients were randomly assigned to receive
capsules of control (olive oil, OO) 4 g/d, OM3-CA 2 g/d (plus OO 2 g/d), or OM3-CA 4 g/d for 6 weeks.
Results: Compared with OO, low-density lipoprotein (LDL) particle size was increased with OM3-CA 2 g/d (p < 0.01)
and 4 g/d (p < 0.001), and very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) particle sizes were
decreased with both OM3-CA dosages vs. OO (p < 0.001 and p < 0.05 for VLDL and HDL, respectively). Total
VLDL/chylomicron remnant particle concentration was reduced by 8.5 and 16.0 % with OM3-CA 2 and 4 g/d,
respectively, vs. a 6.9 % reduction with OO (p < 0.001 for OM3-CA 4 g/d vs. OO). Total HDL particle concentration was
also reduced by 1.5 and 3.2 % with OM3-CA 2 and 4 g/d, respectively, vs. a 0.6 % increase with OO (at least
p < 0.05 for both comparisons). Changes in total LDL particle concentration were not significantly different for
OO vs. OM3-CA at either dosage. Apolipoprotein (Apo) CIII levels decreased by 7.6 and 13.1 % with OM3-CA 2 and 4 g/d,
respectively, vs. 3.2 % with OO (p < 0.001 for OM3-CA 4 g/d vs. OO). Lipoprotein-associated phospholipase A2
(Lp-PLA2) mass was reduced by 6.2 and 10.7 % with OM3-CA 2 and 4 g/d, respectively, vs. a 0.1 % increase with OO
(p < 0.001 for both vs. OO). There were no significant differences between treatments in high-sensitivity C-reactive
protein responses.
Conclusion: OM3-CA were associated with shifts in lipoprotein particle sizes and concentrations, and reductions
in Apo CIII and Lp-PLA2, in patients with hypertriglyceridemia while taking a statin.
Trial registration: ClinicalTrials.gov Identifier NCT01408303.
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Background
The long-chain omega-3 polyunsaturated fatty acids ei-
cosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) have been used therapeutically as agents to treat
hypertriglyceridemia [1]. A mixture of highly bioavail-
able omega-3 carboxylic acids (OM3-CA; Epanova®,
AstraZeneca, Wilmington, DE, USA) [2] has been
shown to significantly reduce triglycerides (TG) and
non-high-density lipoprotein cholesterol (non-HDL-C)
levels at dosages of 2 and 4 g/d when administered to
patients with severe hypertriglyceridemia (≥5.6 mmol/L
[500 mg/dL]) [3] and to statin-treated patients with
TG ≥2.3 mmol/L (200 mg/dL) and <5.6 mmol/L
(500 mg/dL) and at high risk for a cardiovascular
disease (CVD) event [4].
In addition to their lipoprotein lipid–altering effects,
omega-3 fatty acids reportedly affect lipoprotein particle
subclass sizes and concentrations, including a shift
toward an increased proportion of larger, buoyant
LDL particles vs. smaller, denser, and potentially more
atherogenic, LDL particles [5–7]. Omega-3 fatty acids
have also been shown to reduce levels of apolipopro-
tein (Apo) CIII [4, 6, 7]. This is potentially important
clinically because Apo CIII inhibits lipoprotein lipase
activity and hepatic uptake of TG-rich lipoproteins
[8–11], and Apo CIII associated with Apo B–containing
particles is an independent predictor of CVD event risk
[12]. Moreover, loss-of-function polymorphisms in the
Apo CIII gene (APOC3) have been associated with lower
TG and reduced coronary and ischemic vascular disease
risks [13–15].
The present paper reports analyses from the Epanova
combined with a Statin in Patients with hypertRiglyc-
erIdemia to reduce non-HDL cholesTerol (ESPRIT) study,
a randomized, controlled, double-blind, parallel-group,
phase III clinical trial regarding the effects of OM3-CA at
two dosages (2 and 4 g/d), compared with an olive oil
(OO) control, on lipoprotein particle and subclass sizes
and concentrations, as well as other cardiovascular risk
markers, including circulating levels of Apo CIII, and the
inflammatory markers lipoprotein-associated phospholip-
ase A2 (Lp-PLA2) and high-sensitivity C-reactive protein
(hs-CRP) [16], in high-CVD-risk, statin-treated patients
with residual hypertriglyceridemia.
The primary results from this study, reported previ-
ously [4], showed that 2- and 4-g/d dosages of OM3-
CA, compared with OO control, significantly lowered
TG (14.6 and 20.6 %, respectively, vs. 5.9 %) and
non-HDL-C (3.9 and 6.9 %, respectively, vs. 0.9 %)
(all p < 0.05 or lower). Total cholesterol (total-C) and
VLDL-C concentrations were also reduced vs. OO
with both OM3-CA dosages, and the total-C/HDL-C
ratio and Apo AI and Apo B levels were significantly
reduced vs. OO with 4 g/d only (all at least p < 0.05).
LDL-C significantly increased with OM3-CA 2 g/d
(4.6 %), compared with OO (1.1 %; p = 0.025), but not
with OM3-CA 4 g/d (1.3 %). Percent changes from
baseline in HDL-C did not differ significantly between
OO and either OM3-CA dosage group.
Results
Patients
As described previously [4], 647 patients were
randomized — 216 to OO, 215 to OM3-CA 2 g/d
(plus OO 2 g/d), and 216 to OM3-CA 4 g/d — and
623 patients completed the study. The results reported
herein are from the 627 patients in the intent-to-treat
population. There were no significant differences be-
tween treatment groups in demographic characteristics,
statin use, or the intensity of the statins used. Patients
were primarily non-Hispanic/non-Latino (82.6 %) and
white (94.1 %) men (59.1 %) with a mean (standard devi-
ation) age of 60.8 (9.6) years. Most of the patients used a
statin alone (95.3 %), and the majority used low-intensity
statins (56.0 %).
Lipoprotein particle sizes and concentrations
Baseline, end-of-treatment, and LSM-BT percent change
from baseline values for lipoprotein particle sizes and
concentrations are presented in Table 1. The LDL par-
ticle size was significantly increased and the VLDL and
HDL particle sizes were significantly reduced with both
OM3-CA 2- and 4-g/d dosages vs. OO. Baseline and
changes from baseline in LDL particle size according
to the end-of-treatment TG concentration categories
of <1.7 (150), 1.7–2.2 (150–199), and ≥2.3 (200) mmol/L
(mg/dL), respectively, are shown in Table 2. There was a
significant (p < 0.001) inverse correlation (Spearman’s rho)
between changes in TG and LDL particle size in all treat-
ment groups: OO −0.283, OM3-CA 2 g/d −0.244, and
OM3-CA 4 g/d −0.242.
OM3-CA lowered the concentration of VLDL/chylo-
micron remnants, but only the OM3-CA 4 g/d response
reached statistical significance vs. OO. Large VLDL/
chylomicron remnant particles were reduced signifi-
cantly vs. OO in both OM3-CA groups, medium VLDL
particles were reduced significantly vs. OO only in the
4 g/d group, and no significant differences between
groups were observed for the small VLDL particle con-
centration response.
Responses in total LDL and intermediate-density
lipoprotein (IDL) particle concentrations did not dif-
fer significantly between treatments. The concentra-
tion of large LDL particles was reduced markedly
from baseline in the OO group and reduced to a sig-
nificantly smaller extent in both of the OM3-CA
groups. Small LDL particle concentration was relatively
unchanged from baseline in the OO and OM3-CA 2 g/d
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Table 1 Baseline, end-of-treatment, and percent change values for lipoprotein particle sizes and concentrationsa,b
Statin + OO Statin + OM3-CA Statin + OM3-CA
4 g/d 2 g/dc 4 g/d
Variable (n = 211) (n = 209) (n = 207)
Lipoprotein particle sizes
VLDL (nm)
Baseline 55.0 (5.7) 55.4 (5.6) 55.2 (5.9)
End-of-treatment 54.7 (5.9) 52.2 (5.4) 50.8 (5.8)
%Δ LSM-BT (95 % CI) −0.6 (−1.7, 0.4) −5.6 (−6.6, −4.6)*** −8.0 (−9.0, −7.0)***
LDL (nm)
Baseline 19.9 (0.4) 19.9 (0.3) 19.9 (0.4)
End-of-treatmentd 19.9 (0.4) 20.0 (0.4) 20.1 (0.4)
%Δ LSM-BT (95 % CI) −0.1 (−0.2, 0.1) 0.3 (0.1, 0.5)** 0.6 (0.4, 0.8)***
HDL (nm)
Baseline 8.5 (0.3) 8.5 (0.3) 8.5 (0.3)
End-of-treatment 8.5 (0.3) 8.4 (0.3) 8.4 (0.4)
%Δ LSM-BT (95 % CI) −0.2 (−0.5, 0.1) −0.6 (−0.9, −0.2)* −0.5 (−0.9, −0.2)*
Lipoprotein particle concentrations
Total VLDL/chylomicron remnant (nmol/L)
Baseline 129 (47.0) 128 (43.0) 130 (48.2)
End-of-treatment 123 (53.4) 119 (47.0) 114 (54.4)
%Δ LSM-BT (95 % CI) −6.9 (−11.1, −2.5) −8.5 (−12.6, −4.1) −16.0 (−19.8, −12.0)**
Large VLDL/chylomicron remnant (nmol/L)
Baseline 13.2 (7.2) 14.0 (7.4) 13.9 (8.3)
End-of-treatment 12.7 (7.9) 9.6 (7.3) 7.5 (6.8)
%Δ LSM-BT (95 % CI) −10.1 (−17.5, −2.0) −36.8 (−42.0, −31.1)*** −55.8 (−59.5, −51.8)***
Medium VLDL (nmol/L)
Baseline 72.1 (30.9) 69.7 (32.2) 72.0 (37.4)
End-of-treatment 68.4 (35.5) 62.9 (33.2) 60.0 (36.3)
%Δ LSM-BT (95 % CI) −9.7 (−15.5, −3.5) −12.6 (−18.2, −6.5) −22.8 (−27.8, −17.4)*
Small VLDL (nmol/L)
Baseline 43.5 (31.1) 44.3 (25.5) 44.2 (29.5)
End-of-treatment 42.4 (30.4) 46.8 (28.3) 46.8 (30.4)
%Δ LSM-BT (95 % CI) −1.1 (−10.1, 8.7) 4.7 (−4.8, 15.3) 8.6 (−1.4, 19.6)
Total LDL (nmol/L)
Baseline 1286 (360) 1309 (357) 1323 (342)
End-of-treatment 1317 (374) 1359 (391) 1359 (378)
%Δ LSM-BT (95 % CI) 2.0 (−0.6, 4.5) 3.3 (0.8, 6.0) 2.4 (−0.2, 5.0)
IDL (nmol/L)
Baseline 74.9 (77.2) 79.0 (78.5) 75.5 (76.6)
End-of-treatment 75.6 (92.0) 72.9 (73.8) 70.7 (78.9)
%Δ LSM-BT (95 % CI) −13.5 (−25.2, 0.2) −6.9 (−19.7, 7.8) −15.7 (−27.3, −2.3)
Large LDL (nmol/L)
Baseline 661 (576) 660 (569) 656 (592)
End-of-treatment 389 (408) 439 (440) 445 (407)
%Δ LSM-BT (95 % CI) −49.8 (−58.5, −39.3) −40.1 (−50.6, −27.4)*** −21.6 (−35.4, −4.7)***
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groups, whereas there was a small decline in the OM3-
CA 4 g/d group that reached statistical significance, com-
pared with the OO response.
Total HDL particle concentration declined statistically
significantly, compared with OO in both OM3-CA
dosage groups. Reductions in large and small HDL par-
ticle concentrations contributed to these effects, as both
were reduced, compared with the responses in the OO
group, whereas medium HDL particle concentration in-
creased in both OM3-CA dosage groups vs. OO.
Table 1 Baseline, end-of-treatment, and percent change values for lipoprotein particle sizes and concentrationsa,b (Continued)
Small LDL (nmol/L)
Baseline 1004 (310) 1014 (313) 1033 (296)
End-of-treatment 1024 (325) 1023 (331) 1008 (334)
%Δ LSM-BT (95 % CI) 1.0 (−2.7, 4.7) 0.3 (−3.3, 4.1) −4.2 (−7.7, −0.7)*
Total HDL (mmol/L)
Baseline 32.8 (5.8) 32.7 (6.2) 32.6 (6.8)
End-of-treatment 33.0 (6.1) 32.3 (6.1) 31.6 (6.7)
%Δ LSM-BT (95 % CI) 0.6 (−0.7, 1.9) −1.5 (−2.8, −0.2)* −3.2 (−4.5, −1.9)***
Large HDL (mmol/L)
Baseline 2.6 (1.9) 2.4 (1.8) 2.4 (1.9)
End-of-treatment 2.6 (1.8) 2.2 (2.0) 2.2 (2.3)
%Δ LSM-BT (95 % CI) −6.9 (−20.9, 9.5) −39.0 (−48.2, −28.1)*** −29.0 (−39.8, −16.3)***
Medium HDL (mmol/L)
Baseline 6.0 (3.2) 6.1 (3.4) 6.5 (5.1)
End-of-treatment 5.9 (3.4) 6.3 (3.3) 6.7 (3.5)
%Δ LSM-BT (95 % CI) −6.6 (−12.2, −0.7) 3.9 (−2.4, 10.5)* 11.3 (4.6, 18.4)***
Small HDL (mmol/L)
Baseline 24.1 (4.7) 24.2 (4.5) 23.7 (4.9)
End-of-treatment 24.5 (5.0) 23.7 (4.8) 22.7 (4.6)
%Δ LSM-BT (95 % CI) 1.7 (−1.0, 4.4) −1.9 (−4.5, 0.7)** −3.6 (−6.1, −1.0)***
Abbreviations: %Δ percent change, CI confidence interval, HDL high-density lipoprotein, IDL = intermediate-density lipoprotein, LDL low-density lipoprotein, LSM-BT
least-squares means–back transformed, OM3-CA omega-3 carboxylic acids, OO Olive oil, VLDL very low-density lipoprotein
aMeans (standard deviation) are presented for baseline and end-of-treatment values
bSuperscript letters represent p-values for each OM3-CA dosage vs. OO: *p < 0.05, **p < 0.01, and ***p < 0.001
cPatients in the OM3-CA 2 g/d treatment arm also received OO capsules at a dosage of 2 g/d
dNumber of patients with data in the OM3-CA 2 g/d treatment group = 208
Table 2 Baseline and change in low-density lipoprotein particle size by end-of-treatment triglyceride category
End-of-treatment TG category and Statin + OO Statin + OM3-CA Statin + OM3-CA
LDL particle size 4 g/d 2 g/da 4 g/d
Mean (95 % CI)
TG <1.7 mmol/L (<150 mg/dL) (n = 15) (n = 14) (n = 33)
Baseline LDL particle size (nm) 20.33 (20.09, 20.57) 20.10 (19.89, 20.31) 20.17 (20.03, 20.31)
Δ from baseline LDL particle size (nm) 0.22 (0.03, 0.41) 0.15 (0.00, 0.30) 0.31 (0.17, 0.45)
TG 1.7–2.2 mmol/L (150–199 mg/dL) (n = 33) (n = 52) (n = 54)
Baseline LDL particle size (nm) 20.12 (19.96, 20.28) 20.03 (19.95, 20.11) 20.05 (19.93, 20.17)
Δ from baseline LDL particle size (nm) 0.09 (−0.03, 0.21) 0.10 (0.04, 0.16) 0.17 (0.09, 0.25)
TG ≥2.3 mmol/L (≥200 mg/dL) (n = 163) (n = 142) (n = 120)
Baseline LDL particle size (nm) 19.87 (19.82, 19.92) 19.89 (19.83, 19.95) 19.82 (19.77, 19.87)
Δ from baseline LDL particle size (nm) −0.05 (−0.09, −0.01) 0.05 (0.00, 0.10) 0.04 (0.00, 0.08)
Abbreviations: Δ change, CI confidence interval, LDL low-density lipoprotein, OM3-CA omega-3 carboxylic acids, OO olive oil, TG triglycerides
aPatients in the OM3-CA 2 g/d treatment arm also received OO capsules at a dosage of 2 g/d
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Apo CIII, Lp-PLA2, and hs-CRP
Apo CIII decreased from baseline to end-of-treatment
mean (standard deviation) concentrations of 15.0 (3.9)
to 14.7 (4.1) mg/dL in the OO group, from 15.3 (3.9) to
14.2 (3.9) mg/dL in the OM3-CA 2 g/d group, and from
15.5 (4.0) to 13.4 (3.8) mg/dL in the OM3-CA 4 g/d
group. Lp-PLA2 concentrations changed from 214 (50.2)
to 215 (53.3) ng/mL, from 218 (54.7) to 205 (52.5) ng/mL,
and from 216 (50.1) to 194 (51.4) ng/mL in the OO,
OM3-CA 2 g/d, and OM3-CA 4 g/d groups, respect-
ively. LSM-BT percent changes from baseline in Apo
CIII and Lp-PLA2 concentrations are shown in Fig. 1.
The reduction from baseline in Apo CIII concentration
was significantly greater with OM3-CA 4 g/d vs. OO,
but the comparison of the OM3-CA 2 g/d vs. OO re-
sponses did not reach statistical significance. Lp-PLA2
was significantly reduced from baseline with both the
OM3-CA 2- and 4-g/d dosages, compared with the OO
response. Mean (standard deviation) hs-CRP concentra-
tions in the OO, OM3-CA 2 g/d, and OM3-CA 4 g/d
groups, respectively, changed from 4.2 (5.7) to 4.1
(5.5) mg/L, a LSM-BT reduction of 2.8 %; from 3.9 (6.1) to
3.5 (4.2) mg/L, a 1.2 % increase; and from 4.2 (5.1) to 4.1
(6.1) mg/L, a 4.6 % reduction. LSM-BT percent changes
from baseline in hs-CRP did not differ significantly be-
tween treatments.
Discussion
In men and women with persistent hypertriglyceridemia
while taking a statin, OM3-CA (a mixture of highly bio-
available omega-3 carboxylic acids whose main compo-
nents are EPA, DHA, and dososapentaenoic acid) reduced
mean VLDL/chylomicron particle size and concentration,
increased mean LDL particle size without altering LDL
particle concentration, and reduced mean HDL particle
size and concentration. OM3-CA therapy also reduced
circulating levels of Apo CIII and Lp-PLA2, but did not
change hs-CRP concentration.
In an examination of 4.0 g/d of omega-3 acid ethyl es-
ters (mainly EPA + DHA) in combination with simva-
statin 20 mg/d, compared with placebo + simvastatin
administered to patients with mixed dyslipidemia, VLDL
particle size and concentration decreased, and LDL par-
ticle size significantly increased (all p < 0.05) without a
change in LDL particle concentration [5]. Similarly,
when the dosage of simvastatin was 40 mg/d, compared
with placebo, EPA +DHA ethyl esters reduced mean
VLDL particle size and increased LDL particle size [6].
The total VLDL and LDL particle concentrations were
not altered by omega-3 treatment, relative to placebo
(corn oil), but large VLDL and IDL particle concentra-
tions were lowered and large LDL particle concentration
was increased [6]. A study in mixed dyslipidemia of lipo-
protein particle size and concentration changes with
atorvastatin in combination with omega-3 acid ethyl es-
ters vs. atorvastatin with placebo also demonstrated a
mean increase in LDL particle size accompanied by a re-
duction in small LDL particle concentration and an in-
crease in large LDL particle concentration [7].
The control-corrected increase in large LDL particle
concentration in the 4.0 g/d OM3-CA group in the
present study was similar to that observed in other
studies with comparable dosages of omega-3 ethyl ester
therapy in statin-treated patients [6, 7], despite higher
baseline levels of large LDL particles in the present
trial. The baseline small LDL particle concentration
was lower in the current study than that in other simi-
lar trials [6, 7]. A modest increase in small LDL particle
concentration was observed, whereas reductions oc-
curred in the other trials [6, 7]. However, it should be
noted that the on-treatment value for small LDL parti-
cles in the 4.0 g/d OM3-CA group remained below the
on-treatment levels in other trials [6, 7]. Accordingly,
Fig. 1 Percent changes from baseline in apolipoprotein CIII and lipoprotein-associated phospholipase A2 concentrations. Patients in the
statin + OM3-CA 2 g/d group also received OO control at a dosage of 2 g/d. Superscript asterisks represent a significant difference vs. OO control
(p < 0.001). Abbreviations: Apo = apolipoprotein, Lp-PLA2 = lipoprotein-associated phospholipase A2, LSM-BT = least-squares means–back transformed,
OM3-CA = omega-3 carboxylic acids, OO = olive oil
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the authors believe that the most likely explanation for
the difference between studies in small LDL particle re-
sponses was the lower pre-treatment small LDL particle
concentration in the current trial.
Some, but not all, studies have shown increases in
LDL-C with omega-3 fatty acids therapy in patients with
high or very high TG [17–19]. This effect appears to be
attributable to DHA, as EPA alone has not been shown
to raise LDL-C [20, 21]. The increased cholesterol is
probably the result of an increase in mean LDL particle
size, because trials in mixed dyslipidemia have consist-
ently shown no increase in LDL particle concentration
[5, 7]. In the present study, the results of the exploratory
analysis of the relationship between LDL particle size
and TG changes demonstrate that on-treatment TG
level is an important determinant of the change in LDL
particle size, and provide further support for the proposed
threshold phenomenon, wherein TG must drop below a
threshold for conversion from small, dense to larger, more
buoyant LDL particles [6, 22, 23]. This TG threshold is
specific to each individual, but is usually within the range
of 1.1–2.8 mmol/L (100–250 mg/dL) [6, 22, 23].
Studies of prescription omega-3 acid ethyl ester ther-
apy in statin-treated patients have shown that HDL-C is
either increased modestly or unchanged [5, 6]; however,
the concentration of HDL particles (as well as Apo AI)
consistently declines [5, 6], as was observed in the
present trial. The decrease in HDL particle concentra-
tion with omega-3 therapy is often accompanied by a
modest elevation in HDL-C, which may reflect an in-
crease in the quantity of cholesterol carried per HDL
particle. Results from animal models suggest that fish oil
enhances the cholesterol efflux capacity of HDL [24, 25].
Proteome changes with omega-3 therapy also support a
potential improvement in HDL functionality, although
enhanced cholesterol efflux capacity (a measure of HDL
functionality) with omega-3 therapy in humans has not
been demonstrated to date [26]. If confirmed in humans,
this would have potential clinical relevance, because
cholesterol efflux capacity has been found to be a better
predictor of CVD risk than the HDL-C concentration
[27]. At present, the clinical importance of changes in
HDL-C, HDL particle and HDL particle subclass levels
with omega-3 therapy are uncertain.
The present study also adds further evidence that
omega-3 therapy lowers circulating concentrations of
Apo CIII and Lp-PLA2. Elevated levels of both Apo CIII
[8, 9, 11, 12] and Lp-PLA2 [28–30] have been associated
with increased CVD event risk beyond that attributable
to traditional risk factors. Previous studies with 4 g/d of
EPA +DHA ethyl esters have shown statistically signifi-
cant reductions of 11.5 % to 13.1 % in Apo CIII when
added to statin therapy [6, 7]. Apo CIII in the current
study was reduced by 7.6 % and 13.1 % with OM3-CA
2- and 4-g/d dosages, respectively, compared with a re-
duction of 3.2 % in the OO group (p < 0.001 for OM4-
CA 4 g/d vs. OO).
The role that Apo CIII plays in the pathogenesis of
hypertriglyceridemia is becoming increasingly evident
[9, 10, 31]. Apo CIII inhibits the actions of lipoprotein
lipase and hepatic lipase, thereby slowing TG hydro-
lysis, and it interferes with the interaction between
TG-rich lipoproteins and hepatic Apo B/E receptors,
further slowing TG removal from circulation [32–34].
The severity of hypertriglyceridemia is positively asso-
ciated with the level of Apo CIII [9]. It has been sug-
gested that an increase in Apo CIII synthesis in
hypertriglyceridemia may represent a compensatory
mechanism to reduce the catabolism of TG-rich lipo-
proteins and uptake by hepatic receptors in an attempt
to cope with a large influx of substrates for TG produc-
tion. In the present study, it was not possible to deter-
mine whether the reduction in Apo CIII was
attributable to reduced production, increased clearance
from circulation, or some combination. Regardless, it is
likely that reducing Apo CIII with omega-3 fatty acid
treatment contributes to TG lowering by enhancing the
rate of TG clearance and/or reducing hepatic VLDL-
TG secretion [35–37], and that Apo CIII may therefore
also play a role in the non-HDL-C–lowering effect of
OM3-CA.
Previous studies with 4 g/d of EPA +DHA ethyl esters
have shown statistically significant reductions of 5.1 to
11.0 % in Lp-PLA2 when added to statin therapy [6, 7]. In
the present study, Lp-PLA2 was reduced by 6.2 % and
10.7 % with OM3-CA 2 and 4 g/d, respectively, compared
with a change of +0.1 % in the OO group (p < 0.001 for
both dosages vs. OO). Of interest is that fenofibrate and
niacin increase Lp-PLA2 when added to a statin [38, 39].
Omega-3 fatty acid treatment is the only lipid-altering
therapy identified to date that lowers Lp-PLA2 mass
without lowering LDL-C. Lp-PLA2 in circulation is a
marker for secretion of PLA2 by macrophages in the
arterial wall in response to inflammatory stimuli [40].
The clinical relevance of a reduction in Lp-PLA2 is un-
certain at present, particularly in light of results from
two clinical outcomes trials that failed to demonstrate
reduced CVD event risk with darapladib, an oral, se-
lective inhibitor of the Lp-PLA2 enzyme [41, 42]. As
with Apo CIII, it is not possible in the present study to
determine whether reduced Lp-PLA2 in response to
omega-3 therapy resulted from reduced secretion of
PLA2, reduced association of PLA2 with lipoproteins,
or enhanced removal from circulation.
hs-CRP is an inflammatory marker, and an elevated
level is associated with increased CVD risk [16, 43]. The
present results affirm that OM3-CA does not signifi-
cantly alter hs-CRP levels, which is consistent with
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results from other studies that have reported no effect of
omega-3 fatty acid therapy on hs-CRP levels in statin-
treated hypertriglyceridemic individuals [6, 7].
Although the results herein demonstrate that OM3-
CA result in potentially favorable changes in lipoprotein
particle concentrations and sizes, Apo CIII, and Lp-
PLA2, similar to those shown for ethyl ester forms [5–7],
they are limited in that they do not provide a mechanis-
tic explanation for the changes observed, nor do they
measure the impact on CVD risk. An Outcomes Study
to Assess STatin Residual Risk Reduction with EpaNova
in HiGh Cardiovascular Risk PatienTs with Hypertriglyc-
eridemia (STRENGTH) is ongoing and will answer the
question of the effects of OM3-CA on CVD risk (http://
clinicaltrials.gov/show/NCT02104817). Another poten-
tial limitation that has been described previously [4] was
the use of an OO control, which may have had non-
neutral effects on some of the outcome variables. The
control in the STRENGTH trial is corn oil.
Conclusions
In men and women with persistent hypertriglyceridemia
while taking statins, OM3-CA (a mixture of highly
bioavailable omega-3 carboxylic acids whose major
components are EPA, DHA, and docosapentaenoic
acid) reduced the concentrations and sizes of VLDL/
chylomicron remnant and HDL particles and increased
LDL particle size without affecting LDL particle con-
centration. In addition, OM3-CA therapy reduced cir-
culating levels of Apo CIII and Lp-PLA2, but did not
change hs-CRP concentration. The potentially favorable
changes in LDL particle size, Apo CIII, and Lp-PLA2
might contribute to reduced CVD risk with OM3-CA
therapy; however, this remains to be demonstrated in
clinical outcomes trials.
Methods
Study design and patients
ESPRIT was a trial conducted at 96 research sites in
the United States. A list of the principal investigators
and investigative sites is included in the Appendix.
The full details of the study design and patient inclu-
sion and exclusion criteria were published previously
[4]. In brief, patients underwent a 6-week statin
stabilization/National Cholesterol Education Program
(NCEP) Therapeutic Lifestyle Changes diet lead-in
period [44], after which those who met the eligibility
criteria were randomized in approximately equal
numbers to receive either OO 4 g/d, OM3-CA 2 g/d
plus OO 2 g/d, or OM3-CA 4 g/d for 6 weeks in
combination with the same dose of statin they were
taking during the lead-in period. Good Clinical Practice
Guidelines, the Declaration of Helsinki (2000), and the
United States 21 Code of Federal Regulations were
followed in the conduct of the study. An appropriately
constituted Institutional Review Board approved the clin-
ical protocol before the study started. All patients signed
an informed consent form and provided authorization for
disclosure of protected health information before under-
going any protocol-specific procedures.
Subjects included in the study were men and non-
pregnant, non-lactating women ≥18 years of age with
fasting TG ≥2.3 mmol/L (200 mg/dL) and <5.6 mmol/L
(500 mg/dL) (after the statin/diet lead-in), at high risk
for a future cardiovascular event, and at or near the
NCEP goal for low-density lipoprotein cholesterol
(LDL-C) (≤110 % of NCEP Adult Treatment Panel III
LDL-C goal) [44] or on a maximally tolerated statin
dose (stable for at least 4 weeks prior to screening).
Disallowed agents included fish oil or any EPA- or
DHA-containing products, medications, or investiga-
tional drugs within 6 weeks before randomization;
and fibrates, bile acid sequestrants, niacin and its an-
alogues >200 mg/d, simvastatin 80 mg, or any dietary sup-
plement for the purpose of cholesterol lowering at
screening or during the study. Subjects were instructed to
follow the Therapeutic Lifestyle Changes diet and continue
their routine activity levels throughout the study.
Exclusion criteria included a non-HDL-C level
<2.3 mmol/L (90 mg/dL); known lipoprotein lipase
impairment or deficiency, Apo CII deficiency, or fa-
milial dysbetalipoproteinemia; history of pancreatitis;
type 1 diabetes mellitus, use of insulin, or glycated
hemoglobin >10 %; poorly controlled hypertension;
recent significant nephrotic syndrome or pulmonary,
hepatic, biliary, gastrointestinal, or immunologic dis-
ease; cancer (except non-melanoma skin cancer or
carcinoma in situ of the cervix); or clinically import-
ant clinical laboratory values at screening.
Laboratory methods
Lipoprotein particle subclass concentrations and sizes
were analyzed by LipoScience, Inc. (Raleigh, NC, USA),
using the Nuclear Magnetic Resonance LipoProfile®
method [45] on serum obtained from fasting (9–14 hr)
blood samples collected at weeks −1 and 0 (values were
averaged to calculate baseline) and weeks 5 and 6 of
treatment (values were averaged to calculate end of
treatment). Analyses of Apo CIII, Lp-PLA2, and hs-CRP
were performed by Medpace Reference Laboratories
(Cincinnati, OH, USA) on serum obtained from fasting
serum samples collected at week 0 (baseline) and week 6
(end of treatment). Apo CIII concentrations were mea-
sured using the Randox Apo CIII test, which utilizes an
in vitro turbidimetric immunoassay and the Randox
Daytona analyzer (Kearneysville, WV, USA). Lp-PLA2
mass was determined by a latex particle–enhanced tur-
bidimetric immunoassay on a Roche-P modular analyzer
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(PLAC™ test, Diadexus, San Francisco, CA, USA) [46].
hs-CRP was measured by nephelometry on a Siemens
BNII nephelometer (Malvern, PA, USA).
Statistical analyses
SAS (SAS Institute, Cary, NC, version 9.2) was used for
statistical programming and analyses. End points in-
cluded percent changes from baseline to end of treat-
ment in lipoprotein particles (sizes, concentrations, and
subclasses for very low-density lipoprotein [VLDL],
LDL, and HDL), Apo CIII, Lp-PLA2, and hs-CRP. Effi-
cacy end points for each OM3-CA arm were compared
with OO using analysis of covariance, with the baseline
value as a covariate and treatment group and statin in-
tensity as factors. Low-intensity statins (defined as those
expected to lower LDL-C by <40 % in patients with pri-
mary hyperlipidemia) included lovastatin 20–40 mg,
pravastatin 10–80 mg, fluvastatin 20–80 mg, simvastatin
10–20 mg, atorvastatin 10–20 mg, and rosuvastatin
10 mg; high-intensity statins included simvastatin 40 mg,
atorvastatin 40–80 mg, and rosuvastatin 20–40 mg
[47, 48]. The response in each OM3-CA treatment
group was compared to OO at a significance level of
alpha = 0.05, two-sided, without adjustment for mul-
tiple comparisons. For patients who terminated par-
ticipation prior to completing the full treatment
period, the value of the previous post-randomization
observation was carried forward. The Shapiro-Wilk
test was run on the model residuals to investigate
normality assumptions. Values were ranked prior to
the final analysis if the normality assumption was
rejected at p < 0.01. Because rank transformed data
cannot be back-transformed into meaningful units, when
they were used to generate p-values, models were also run
using natural log-transformed values to produce least-
squares means–back transformed (LSM-BT) and 95 %
confidence intervals (CIs) for response values.
An exploratory analysis was performed that examined
the baseline and changes from baseline in LDL particle
size for patients according to their end-of-treatment
TG category classified as <1.7 (150), 1.7–2.2 (150–199),
or ≥2.3 (200) mmol/L (mg/dL) [44]. Univariate Spearman
rank correlation coefficients within each treatment arm
were calculated for the change from baseline LDL particle
size as the dependent variable and change from baseline
in TG concentration as the independent variable.
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